NEW YORK (GenomeWeb News) – Epigenomics announced today that Swiss Life will provide insurance coverage for the firm's Epi proColon 2.0 colorectal cancer test as part of a preventive health program in France.
Swiss Life, France's third-largest private health insurer, is the first French insurer to cover the test, which uses Epigenomics' colorectal cancer biomarker Septin9 in blood plasma, and will reimburse for the test at up to 50 percent of the cost. French Social Security does not cover Epi proColon 2.0, Berlin-based Epigenomics noted.
Epigenomics CEO Geert Nygaard said in a statement that the coverage decision "clearly confirms our recently implemented commercialization approach in Europe under which we are working closely with key players in the healthcare system."
The test is CE marked in Europe, and Epigenomics is in the process of applying to the US Food and Drug Administration for marketing clearance.